Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
First Claim
1. A method for treating a disease or disorder with an underlying dysregulation of the emotional functionality comprising, administering to a patient pipamperon in a dose ranging between 5 and 15 mg of the active ingredient, and administering said pipamperon simultaneously with, separate from or sequential to second compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said second compound.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena-etc). The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.
82 Citations
82 Claims
- 1. A method for treating a disease or disorder with an underlying dysregulation of the emotional functionality comprising, administering to a patient pipamperon in a dose ranging between 5 and 15 mg of the active ingredient, and administering said pipamperon simultaneously with, separate from or sequential to second compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said second compound.
-
5. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases or disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, substance related disorder, personality disorders, antisocial behaviour, bereavement, occupational problem and problems related to abuse or neglect and pain disorders, the method comprising administering to a that pipamperon so a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a 5-HT (serotonin) reuptake enhancer compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT (serotonin) reuptake enhancer compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
6-7. -7. (canceled)
-
8. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender disorders, adjustment disorders, impulse control disorders, attention-deficit disorders, substance-related disorder, personality disorders, antisocial behaviour, bereavement, occupational problem and problems related to abuse or neglect, the method comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a 5-HT1A receptor antagonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said 5-HT1A receptor antagonist compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
9-18. -18. (canceled)
-
19. A method for treating the underlying emotion dysregulation of substance related disorders and Parkinson disease, comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a D1 receptor receptor agonist compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said D1 receptor agonist compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
20-25. -25. (canceled)
-
26. A method for treating the underlying emotion dysregulation of Parkinson Disease, comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a levodopa/decarboylase inhibitor compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said levodopa/decarboylase inhibitor compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
27-33. -33. (canceled)
-
34. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, adjustment disorders, attention-deficit disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorder, the method comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a selective nor-adrenaline re-uptake inhibitor (NARI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective nor-adrenaline re-uptake inhibitor (NARI) compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
35. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, sleep disorders, adjustment disorders, impulse control disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, the method comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a noradrenergic/specific serotonergic antidepressant (NaSSA) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said noradrenergic/specific serotonergic antidepressant (NaSSA) compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
36. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, adjustment disorders, attention-deficit disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, the method comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a selective nor-adrenaline and dopamine re-uptake inhibitor (NDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective nor-adrenaline and dopamine re-uptake inhibitor (NDRI) compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
37. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sexual and gender identity disorders, adjustment disorders, impulse control disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, the method comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a compound which is a reversible inhibitor of mono-amine oxydase A (RIMA) to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said compound which is a reversible inhibitor of mono-amine oxydase A (RIMA), further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
38. (canceled)
-
39. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect, pain disorders, delirium, Alzheimer Disease, substance-related persisting dementia, vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson Disease, dementia due to Huntington Disease, dementia due to Pick Disease, dementia due to Creutzfeldt-Jacob Disease, amnestic disorders due to a general medical condition, substance-induced persisting amnestic disorder, mild cognitive impairment disorder and other cognitive disorders, the method comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a selective serotonin and dopamine re-uptake inhibitor (SDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin and dopamine re-uptake inhibitor (SDRI) compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
40. (canceled)
-
41. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, attention-deficit disorders, substance-related disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, the method comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin, nor-adrenaline and dopamine re-uptake inhibitor (SNDRI) compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
42. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, attention-deficit disorders, substance-related disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, the method comprising administering to a patient pipamperon or a pharmaceutically acceptable salt simultaneously with, separate from or prior to the administration of a selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin and nor-adrenaline re-uptake inhibitor (SNRI) compound, further characterized in that pipamperon is to be administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
43. A method for treating the underlying emotion dysregulation of a non-cognitive mental disease or disorder selected from the group of diseases and disorders consisting of mood disorders, anxiety disorders, eating disorders, premenstrual syndrome, somatoform disorders (excluding pain disorders), factitious disorders, dissociative disorders, sleep disorders, adjustment disorders, impulse control disorders, substance-related disorders, personality disorders, antisocial behaviour, bereavement, occupational problem, problems related to abuse or neglect and pain disorders, the method comprising administering to a patient pipamperon or a pharmaceutically acceptable salt thereof simultaneously with, separate from or prior to the administration of a selective serotonin re-uptake inhibitor (SSRI) compound to augment the therapeutic effect or to provide a faster onset of the therapeutic effect of said selective serotonin re-uptake inhibitor (SSRI) compound, further characterized in that pipamperon is administered to said patient in a daily dose ranging between 5 and 15 mg of the active ingredient.
-
44-78. -78. (canceled)
-
79. A method for preparing a compound having a selective D4 and 5-HT2A antagonist, reverse agonist or partial agonist activity comprising the following steps:
- (a) measuring the selective affinity of a test compound to the D4 receptor and selecting a compound that has a pKi value equal to or greater than 8 towards the D4 receptor in respect to all the other D receptors, and measuring the selective efficacy of the selected compound to the D4 receptor and selecting a compounds which is a selective antagonist, inverse agonist or partial agonist of the D4 receptor;
(b) measuring the selective affinity of a test compound to the 5-HT2A receptor and selecting a compound that has a pKi value equal to or greater than 8 towards the 5-HT2A receptor in respect to all the other 5HT receptors, and measuring the selective efficacy of the selected compound to the 5-HT2A receptor and selecting a compounds which is a selective antagonist, inverse agonist or partial agonist of the 5-HT2A receptor;
(c) identifying a compound which is selected in (a) and (b); and
(d) preparing the compound identified in (c). - View Dependent Claims (80)
- (a) measuring the selective affinity of a test compound to the D4 receptor and selecting a compound that has a pKi value equal to or greater than 8 towards the D4 receptor in respect to all the other D receptors, and measuring the selective efficacy of the selected compound to the D4 receptor and selecting a compounds which is a selective antagonist, inverse agonist or partial agonist of the D4 receptor;
Specification